Vermillion Sets 2013 Annual Meeting of Stockholders for Thursday, December 12,
AUSTIN, Texas, Oct. 14, 2013
AUSTIN, Texas, Oct. 14, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, will hold its 2013 Annual Meeting of Stockholders on Thursday,
December 12, 2013 at 8:00 a.m. Central time at the Marriott Hotel located at
300 East Fourth Street in Austin, Texas 78701.
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.
The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.
Press spacebar to pause and continue. Press esc to stop.